Appendiceal adenocarcinoma is one of oncology's orphan diseases — so rare that standard chemotherapy regimens borrowed from colorectal cancer are used largely by default, with minimal evidence of efficacy. That calculus may be changing: emerging data suggest that targeting the KRAS oncogene, which is mutated in the vast majority of appendiceal adenocarcinomas, could offer a genuinely tailored therapeutic strategy for a patient population that has had almost no precision medicine options.
Researchers tested two distinct KRAS-targeting agents — MRTX1133, which specifically locks onto the KRASG12D mutant isoform, and RMC-6236, a pan-KRAS inhibitor active across multiple mutation subtypes — in patient-derived organoids and patient-derived xenograft (PDX) models replicating peritoneal carcinomatosis, the most clinically feared spread pattern of this disease. Both agents achieved sub-nanomolar to low-nanomolar inhibitory concentrations in organoid assays and meaningfully suppressed tumor growth in matched PDX models. Multi-omics profiling confirmed genuine on-target activity through suppression of ERK phosphorylation and downregulation of RAS/ERK and E2F transcriptional programs. Notably, pan-KRAS inhibition also triggered upregulation of interferon-alpha and interferon-gamma pathways, hinting at immune microenvironment engagement that could have implications for combination strategies. Resistance-associated epithelial-to-mesenchymal transition (EMT) signals were also identified, flagging a potential acquired resistance mechanism. A small clinical cohort of 15 patients treated with KRAS inhibitors provided translational corroboration.
This work is significant for several reasons. KRAS was long considered undruggable, but the approval of sotorasib and adagrasib for G12C-mutant lung cancer opened a new era. Appendiceal adenocarcinoma is dominated by G12D and G12V variants rather than G12C, making agents like MRTX1133 and RMC-6236 more directly applicable here than first-generation KRAS inhibitors. The 15-patient clinical cohort is too small to draw survival conclusions, and PDX models notoriously overestimate drug sensitivity in practice. Nevertheless, the mechanistic coherence between preclinical and early clinical signals makes this an incrementally important, potentially practice-informing dataset for a cancer with no established molecular therapy.